10-K Filing

SWK Holdings Corp CIK: 1089907 FY 2023

Filing Information

Form Type	10-K
Accession Number	`0001552781-24-000162`
Period End Date	20231231
Filing Date	20240320
Fiscal Year	2023
Fiscal Period	FY
XBRL Instance	e24067_swkh-10k_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 73 Income Statement 46 Cash Flow Statement 84 Stockholders Equity 18

Balance Sheet 73 line items

Line Item	Tag	Value	Unit	Period
Preferred Stock, Par or Stated Value Per Share	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, Par or Stated Value Per Share	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, Shares Authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred Stock, Shares Authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred Stock, Shares Issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred Stock, Shares Issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$4.50M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$6.16M	USD	Point-in-time
Preferred Stock, Shares Outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Restricted cash	`RestrictedCashEquivalentsCurrent`	$733.00K	USD	Point-in-time
Restricted cash	`RestrictedCashEquivalentsCurrent`	-	USD	Point-in-time
Preferred Stock, Shares Outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Common Stock, Par or Stated Value Per Share	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Interest and accounts receivable, net	`AccountsReceivableNet`	$3.09M	USD	Point-in-time
Common Stock, Par or Stated Value Per Share	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Interest and accounts receivable, net	`AccountsReceivableNet`	$4.73M	USD	Point-in-time
Common Stock, Shares Authorized	`CommonStockSharesAuthorized`	250.00M	shares	Point-in-time
Common Stock, Shares Authorized	`CommonStockSharesAuthorized`	250.00M	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$1.11M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$1.90M	USD	Point-in-time
Common Stock, Shares, Outstanding	`CommonStockSharesOutstanding`	12.50M	shares	Point-in-time
Common Stock, Shares, Outstanding	`CommonStockSharesOutstanding`	12.84M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$11.87M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$10.36M	USD	Point-in-time
Finance receivables, net	`NotesAndLoansReceivableNetCurrent`	$236.56M	USD	Point-in-time
Finance receivables, net	`NotesAndLoansReceivableNetCurrent`	$274.50M	USD	Point-in-time
Collateral on foreign currency forward contract	`DerivativeInstrumentsAndHedges`	$2.75M	USD	Point-in-time
Collateral on foreign currency forward contract	`DerivativeInstrumentsAndHedges`	$2.75M	USD	Point-in-time
Marketable investments	`AvailableForSaleSecuritiesDebtSecurities`	$76.00K	USD	Point-in-time
Marketable investments	`AvailableForSaleSecuritiesDebtSecurities`	$48.00K	USD	Point-in-time
Deferred tax assets, net	`DeferredIncomeTaxAssetsNet`	$24.48M	USD	Point-in-time
Deferred tax assets, net	`DeferredIncomeTaxAssetsNet`	$28.29M	USD	Point-in-time
Warrant assets	`WarrantAssets`	$1.22M	USD	Point-in-time
Warrant assets	`WarrantAssets`	$1.76M	USD	Point-in-time
Goodwill	`Goodwill`	$8.40M	USD	Point-in-time
Goodwill	`Goodwill`	-	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$6.49M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$8.19M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$5.84M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$5.44M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$1.74M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$3.11M	USD	Point-in-time
Total assets	`Assets`	$299.62M	USD	Point-in-time
Total assets	`Assets`	$334.25M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$3.90M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$3.94M	USD	Point-in-time
Revolving credit facility	`LinesOfCreditCurrent`	-	USD	Point-in-time
Revolving credit facility	`LinesOfCreditCurrent`	$2.44M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$3.94M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$6.35M	USD	Point-in-time
Contingent consideration payable	`ContingentConsiderationPayable`	$11.20M	USD	Point-in-time
Contingent consideration payable	`ContingentConsiderationPayable`	$4.90M	USD	Point-in-time
Unsecured senior notes, net	`UnsecuredDebt`	$30.78M	USD	Point-in-time
Unsecured senior notes, net	`UnsecuredDebt`	-	USD	Point-in-time
Revolving credit facility	`LongTermLineOfCredit`	-	USD	Point-in-time
Revolving credit facility	`LongTermLineOfCredit`	$12.35M	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$1.96M	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$2.15M	USD	Point-in-time
Total liabilities	`Liabilities`	$53.94M	USD	Point-in-time
Total liabilities	`Liabilities`	$19.69M	USD	Point-in-time
Preferred Stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred Stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, $0.001 par value; 250,000,000 shares authorized; 12,497,770 and 12,843,157 shares issued and outstanding at December 31, 2023 and 2022, respectively	`CommonStockValue`	$12.00K	USD	Point-in-time
Common stock, $0.001 par value; 250,000,000 shares authorized; 12,497,770 and 12,843,157 shares issued and outstanding at December 31, 2023 and 2022, respectively	`CommonStockValue`	$12.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$4.43B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$4.43B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-4.14B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-4.15B	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$280.31M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$279.93M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$267.24M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$299.62M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$334.25M	USD	Point-in-time

Income Statement 46 line items

Line Item	Tag	Value	Unit	Period
Finance receivable interest income, including fees	`InterestAndFeeIncomeLoansAndLeases`	$36.35M	USD	Annual
Finance receivable interest income, including fees	`InterestAndFeeIncomeLoansAndLeases`	$35.46M	USD	Annual
Pharmaceutical development	`PharmaceuticalDevelopmentRevenue`	$5.49M	USD	Annual
Pharmaceutical development	`PharmaceuticalDevelopmentRevenue`	$1.20M	USD	Annual
Other	`RevenueNotFromContractWithCustomerOther`	$212.00K	USD	Annual
Other	`RevenueNotFromContractWithCustomerOther`	$538.00K	USD	Annual
Total revenues	`Revenues`	$41.48M	USD	Annual
Total revenues	`Revenues`	$37.76M	USD	Annual
Allowance for credit losses	`ProvisionForOtherCreditLosses`	$3.49M	USD	Annual
Allowance for credit losses	`ProvisionForOtherCreditLosses`	$1.91M	USD	Annual
Impairment of goodwill	`GoodwillImpairmentLoss`	$8.40M	USD	Annual
Impairment of goodwill	`GoodwillImpairmentLoss`	-	USD	Annual
Interest expense	`InterestExpense`	$340.00K	USD	Annual
Interest expense	`InterestExpense`	$1.85M	USD	Annual
Pharmaceutical manufacturing, research and development expense	`ResearchAndDevelopmentExpense`	$3.44M	USD	Annual
Pharmaceutical manufacturing, research and development expense	`ResearchAndDevelopmentExpense`	$6.95M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$12.96M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$11.23M	USD	Annual
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	$-6.30M	USD	Annual
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	$5.17M	USD	Annual
Depreciation and amortization expense	`DepreciationAndAmortization`	$2.60M	USD	Annual
Depreciation and amortization expense	`DepreciationAndAmortization`	$2.58M	USD	Annual
Income from operations	`CostsAndExpenses`	$-14.65M	USD	Annual
Income from operations	`CostsAndExpenses`	$-9.97M	USD	Annual
Unrealized net (loss) gain on warrants	`UnrealizedGainLossOnDerivatives`	$-55.00K	USD	Annual
Unrealized net (loss) gain on warrants	`UnrealizedGainLossOnDerivatives`	$417.00K	USD	Annual
Unrealized net loss on equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-528.00K	USD	Annual
Unrealized net loss on equity securities	`MarketableSecuritiesUnrealizedGainLoss`	-	USD	Annual
Realized loss from sale of investments	`MarketableSecuritiesRealizedGainLoss`	$-151.00K	USD	Annual
Realized loss from sale of investments	`MarketableSecuritiesRealizedGainLoss`	$-799.00K	USD	Annual
Foreign currency transaction gain (loss)	`ForeignCurrencyTransactionGainBeforeTax`	$-215.00K	USD	Annual
Foreign currency transaction gain (loss)	`ForeignCurrencyTransactionGainBeforeTax`	$817.00K	USD	Annual
Income before income tax benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$9.49M	USD	Annual
Income before income tax benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$14.61M	USD	Annual
Income tax benefit	`IncomeTaxExpenseBenefit`	$-4.00M	USD	Annual
Income tax benefit	`IncomeTaxExpenseBenefit`	$-1.27M	USD	Annual
Net income	`ProfitLoss`	$13.49M	USD	Annual
Net income	`ProfitLoss`	$15.89M	USD	Annual
Basic	`EarningsPerShareBasic`	$1.26	USD	Annual
Basic	`EarningsPerShareBasic`	$1.05	USD	Annual
Diluted	`EarningsPerShareDiluted`	$1.25	USD	Annual
Diluted	`EarningsPerShareDiluted`	$1.05	USD	Annual
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	12.65M	shares	Annual
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	12.84M	shares	Annual
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	12.88M	shares	Annual
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	12.70M	shares	Annual

Cash Flow Statement 84 line items

Line Item	Tag	Value	Unit	Period
Net income	`ProfitLoss`	$13.49M	USD	Annual
Net income	`ProfitLoss`	$15.89M	USD	Annual
Allowance for credit losses	`ProvisionForOtherCreditLosses`	$3.49M	USD	Annual
Allowance for credit losses	`ProvisionForOtherCreditLosses`	$1.91M	USD	Annual
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$69.00K	USD	Annual
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$493.00K	USD	Annual
Impairment of goodwill	`GoodwillImpairmentLoss`	$8.40M	USD	Annual
Impairment of goodwill	`GoodwillImpairmentLoss`	-	USD	Annual
Right-of-use asset amortization	`FinanceLeaseRightOfUseAssetAmortization`	$333.00K	USD	Annual
Right-of-use asset amortization	`FinanceLeaseRightOfUseAssetAmortization`	$229.00K	USD	Annual
Deferred income taxes	`DeferredIncomeTaxesAndTaxCredits`	$-3.94M	USD	Annual
Deferred income taxes	`DeferredIncomeTaxesAndTaxCredits`	$-1.29M	USD	Annual
Change in fair value of warrants	`FairValueAdjustmentOfWarrants`	$-417.00K	USD	Annual
Change in fair value of warrants	`FairValueAdjustmentOfWarrants`	$55.00K	USD	Annual
Change in fair value of equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-528.00K	USD	Annual
Change in fair value of equity securities	`MarketableSecuritiesUnrealizedGainLoss`	-	USD	Annual
Realized loss from write down of warrant assets	`GainLossOnDispositionOfAssets1`	-	USD	Annual
Realized loss from write down of warrant assets	`GainLossOnDispositionOfAssets1`	$799.00K	USD	Annual
Foreign currency transaction (gain) loss	`ChangeInFairValueOfDerivativeLiability`	$754.00K	USD	Annual
Foreign currency transaction (gain) loss	`ChangeInFairValueOfDerivativeLiability`	$-1.88M	USD	Annual
Loss on sale of marketable securities	`MarketableSecuritiesGainLoss`	$-151.00K	USD	Annual
Loss on sale of marketable securities	`MarketableSecuritiesGainLoss`	-	USD	Annual
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	$-6.30M	USD	Annual
Change in fair value of acquisition-related contingent consideration	`ChangeInFairValueOfAcquisitionrelatedContingentConsideration`	$5.17M	USD	Annual
Loan discount and fee accretion	`AmortizationOfDeferredLoanOriginationFeesNet`	$2.20M	USD	Annual
Loan discount and fee accretion	`AmortizationOfDeferredLoanOriginationFeesNet`	$3.83M	USD	Annual
Interest paid-in-kind	`PaidInKindInterest`	$1.83M	USD	Annual
Interest paid-in-kind	`PaidInKindInterest`	$6.00M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$500.00K	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$509.00K	USD	Annual
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$2.58M	USD	Annual
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$2.60M	USD	Annual
Interest and accounts receivable	`IncreaseDecreaseInInterestAndDividendsReceivable`	$-1.64M	USD	Annual
Interest and accounts receivable	`IncreaseDecreaseInInterestAndDividendsReceivable`	$-1.29M	USD	Annual
Derivative assets and liabilities, net	`DerivativeInstrumentReceivable`	$-539.00K	USD	Annual
Derivative assets and liabilities, net	`DerivativeInstrumentReceivable`	$1.06M	USD	Annual
Collateral on forward currency exchange contract	`IncreaseDecreaseInCollateralOnForwardCurrencyExchangeContract`	-	USD	Annual
Collateral on forward currency exchange contract	`IncreaseDecreaseInCollateralOnForwardCurrencyExchangeContract`	$-2.75M	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$44.00K	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$787.00K	USD	Annual
Accounts payable and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-1.60M	USD	Annual
Accounts payable and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$396.00K	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$14.89M	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$8.20M	USD	Annual
Proceeds from sale of investment and finance receivables	`ProceedsFromSaleOfEquityMethodInvestments`	$13.94M	USD	Annual
Proceeds from sale of investment and finance receivables	`ProceedsFromSaleOfEquityMethodInvestments`	$4.15M	USD	Annual
Investment in finance receivables	`PaymentsToAcquireFinanceReceivables`	$93.12M	USD	Annual
Investment in finance receivables	`PaymentsToAcquireFinanceReceivables`	$74.12M	USD	Annual
Repayment of finance receivables	`ProceedsRepaymentOfFinanceReceivables`	$45.67M	USD	Annual
Repayment of finance receivables	`ProceedsRepaymentOfFinanceReceivables`	$11.70M	USD	Annual
Corporate debt securities principal payments	`MarketableInvestmentPrincipalPayment`	$28.00K	USD	Annual
Corporate debt securities principal payments	`MarketableInvestmentPrincipalPayment`	$43.00K	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$496.00K	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$297.00K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-48.95M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-43.55M	USD	Annual
Net settlement for employee taxes on restricted stock and options	`NetSettlementForEmployeeTaxesOnRestrictedStockAndOptions`	$-160.00K	USD	Annual
Net settlement for employee taxes on restricted stock and options	`NetSettlementForEmployeeTaxesOnRestrictedStockAndOptions`	-	USD	Annual
Payments for financing costs	`PaymentsOfFinancingCosts`	$3.41M	USD	Annual
Payments for financing costs	`PaymentsOfFinancingCosts`	-	USD	Annual
Repurchases of common stock, including fees and expenses	`PaymentsForRepurchaseOfCommonStock`	$6.33M	USD	Annual
Repurchases of common stock, including fees and expenses	`PaymentsForRepurchaseOfCommonStock`	$1.14M	USD	Annual
Proceeds from senior unsecured notes	`ProceedsFromUnsecuredNotesPayable`	-	USD	Annual
Proceeds from senior unsecured notes	`ProceedsFromUnsecuredNotesPayable`	$32.97M	USD	Annual
Net proceeds from revolving credit facilities	`ProceedsFromRepaymentsOfLinesOfCredit`	$9.90M	USD	Annual
Net proceeds from revolving credit facilities	`ProceedsFromRepaymentsOfLinesOfCredit`	$2.44M	USD	Annual
Payment of acquisition-related contingent consideration	`PaymentForContingentConsiderationLiabilityFinancingActivities`	$2.50M	USD	Annual
Payment of acquisition-related contingent consideration	`PaymentForContingentConsiderationLiabilityFinancingActivities`	-	USD	Annual
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-1.36M	USD	Annual
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$33.14M	USD	Annual
Net decrease in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-36.71M	USD	Annual
Net decrease in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-920.00K	USD	Annual
Cash, cash equivalents and restricted cash, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.16M	USD	Point-in-time
Cash, cash equivalents and restricted cash, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$42.86M	USD	Point-in-time
Cash, cash equivalents and restricted cash, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$5.24M	USD	Point-in-time
Cash, cash equivalents and restricted cash, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.16M	USD	Point-in-time
Cash, cash equivalents and restricted cash, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$42.86M	USD	Point-in-time
Cash, cash equivalents and restricted cash, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$5.24M	USD	Point-in-time
Warrants received in connection with finance receivables	`WarrantsReceivedInConjunctionWithPurchaseOfFinancialReceivables`	$1.18M	USD	Annual
Warrants received in connection with finance receivables	`WarrantsReceivedInConjunctionWithPurchaseOfFinancialReceivables`	$1.36M	USD	Annual
Cash paid for interest	`InterestPaidNet`	$1.35M	USD	Annual
Cash paid for interest	`InterestPaidNet`	$268.00K	USD	Annual
Fair value of common stock received upon exercise of warrant	`FairValueOfCommonStockReceivedUponExerciseOfWarrant`	$3.67M	USD	Annual
Fair value of common stock received upon exercise of warrant	`FairValueOfCommonStockReceivedUponExerciseOfWarrant`	-	USD	Annual

Stockholders Equity 18 line items

Line Item	Tag	Value	Unit	Period
Beginning balance, value	`StockholdersEquity`	$280.31M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$279.93M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$267.24M	USD	Point-in-time
Stock-based compensation	`ShareBasedCompensation`	$500.00K	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$509.00K	USD	Annual
Issuance of common stock upon vesting of restricted stock	`StockIssuedDuringPeriodValueNewIssues`	-	USD	Annual
Issuance of common stock upon vesting of restricted stock	`StockIssuedDuringPeriodValueNewIssues`	-	USD	Annual
Net settlement for employee taxes on restricted stock and options	`NetSettlementForEmployeeTaxesOnRestrictedStockAndOptions`	$-160.00K	USD	Annual
Net settlement for employee taxes on restricted stock and options	`NetSettlementForEmployeeTaxesOnRestrictedStockAndOptions`	-	USD	Annual
Stock options exercised, net, Shares	`StockIssuedDuringPeriodSharesStockOptionsExercised`	326,088.00	shares	Annual
Repurchases of common stock in the open market	`StockRepurchasedDuringPeriodValue`	$6.33M	USD	Annual
Repurchases of common stock in the open market	`StockRepurchasedDuringPeriodValue`	$1.14M	USD	Annual
Net income	`NetIncomeLoss`	$13.49M	USD	Annual
Net income	`NetIncomeLoss`	$15.89M	USD	Annual
Effect of adoption of ASU 2016-13	`EffectOfAdoptionOfAccountingStandard`	$-9.68M	USD	Annual
Ending balance, value	`StockholdersEquity`	$280.31M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$279.93M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$267.24M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.